17 Nov 2025
Spotlight on a selection of top Late-breaking Trials presented at PCR London Valves 2025
What's hot and new in valvular and structural interventions
View a snapshot of the results of these 4 trials in valvular and structural interventions presented in London during this year's Heart Team Course!
Table of content
- Safety and Performance of Cardiovalve replacement system for TR: TARGET Study interim results
- Five-year outcomes following early experience with transapical TMVR- Michael Reardon
- TAVI for aortic regurgitation in high surgical risk: Outcomes in 700 patients from ALIGN-AR
- One-year results from the ADALA trial
Safety and Performance of Cardiovalve replacement system for TR: TARGET Study interim results
#PCRLV 2025 Top Late-Breaking Trial results: Tricuspid regurgitation is frequent and disabling, and many patients are inoperable or present with anatomies that are challenging for transcatheter repair . percutaneous valve replacement aims to fill this gap.
Interim 30‑day results from TARGET, presented in London by Georg Nickenig, show that a dedicated transcatheter tricuspid valve can consistently reduce regurgitation with acceptable early safety in high‑risk patients enrolled across Canada, the UK and the EU.
Five-year outcomes following early experience with transapical TMVR
#PCRLV 2025 Top Late-Breaking Trial results: Innovations in structural heart interventions in recent years have rapidly expanded our therapeutic repertoire, but anatomical and technical challenges inherent to mitral valve disease have hindered progress in this area.
The novel data of the 5-year outcomes of the intrepid transapical TMVR system, presented by Michael Reardon in London, demonstrate the safety and efficacy of this pioneering therapy that tackles mitral regurgitation in high-risk patients.
TAVI for aortic regurgitation in high surgical risk: Outcomes in 700 patients from ALIGN-AR
#PCRLV 2025 Top Late-Breaking Trial results: Managing native severe aortic regurgitation in high‑surgical‑risk patients remains difficult. Little or no annular calcium and complex root anatomy make anchoring a valve challenging and options are limited.
In ALIGN-AR, presented in London by Raj R. Makkar, a dedicated transcatheter aortic valve met the predefined 30-day performance goal and showed encouraging 1-year outcomes in this high-risk cohort.
One-year results from the ADALA trial
#PCRLV 2025 Top Late-Breaking Trial results: Managing patients with high thrombotic but also high bleeding risk is a persistent challenge. Left atrial appendage occlusion (LAAO) reduces both thrombotic and bleeding risks in selected patients, however, how to manage the early post-procedure period has remained unclear.
1-year results of the ADALA Trial, presented by Xavier Freixa, in London, show that low-dose Apixaban may be a safer and more effective alternative to conventional therapy.
